GLP-1 Receptor Agonist Effects on Lipid and Liver Profiles in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis
出版年份 2021 全文链接
标题
GLP-1 Receptor Agonist Effects on Lipid and Liver Profiles in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis
作者
关键词
-
出版物
Canadian Journal of Gastroenterology and Hepatology
Volume 2021, Issue -, Pages 1-11
出版商
Hindawi Limited
发表日期
2021-11-13
DOI
10.1155/2021/8936865
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Antioxidative Potentials of Incretin-Based Medications: A Review of Molecular Mechanisms
- (2021) Habib Yaribeygi et al. Oxidative Medicine and Cellular Longevity
- The role of incretins and incretin-based drugs in autoimmune diseases
- (2021) Shabnam Radbakhsh et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Renoprotective Effects of Incretin-Based Therapy in Diabetes Mellitus
- (2021) Habib Yaribeygi et al. Biomed Research International
- The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptydilpeptidase-4 Inhibitors on Blood Pressure and Cardiovascular Complications in Diabetes
- (2021) Habib Yaribeygi et al. Journal of Diabetes Research
- Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
- (2020) Yoshio Sumida et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- GLP-1 mimetics and cognition
- (2020) Habib Yaribeygi et al. LIFE SCIENCES
- Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)
- (2019) M.S. Capehorn et al. DIABETES & METABOLISM
- Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity
- (2019) Habib Yaribeygi et al. LIFE SCIENCES
- Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy
- (2019) Xinyang Yu et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes
- (2019) Habib Yaribeygi et al. LIFE SCIENCES
- Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
- (2019) Golnaz Ranjbar et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Neuromodulatory effects of anti-diabetes medications: A mechanistic review
- (2019) Habib Yaribeygi et al. PHARMACOLOGICAL RESEARCH
- Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
- (2018) Zobair M. Younossi et al. HEPATOLOGY
- Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future
- (2018) Ana Ruth Araújo et al. LIVER INTERNATIONAL
- Liraglutide protects non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in a mouse model induced by high-fat diet
- (2018) Wei Zhu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys
- (2018) Habib Yaribeygi et al. DRUG DISCOVERY TODAY
- Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease
- (2018) Feng Tian et al. BIOSCIENCE REPORTS
- Liraglutide, sitagliptin and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and NAFLD
- (2018) Jinhua Yan et al. HEPATOLOGY
- Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment
- (2017) Vincent Wai-Sun Wong et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease
- (2017) Wenhuan Feng et al. Journal of Diabetes
- Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
- (2016) Matthew J. Armstrong et al. JOURNAL OF HEPATOLOGY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Pioglitazone seems safe and effective for patients with fatty liver disease and diabetes
- (2016) Jacqui Wise BMJ-British Medical Journal
- Pioglitazone seems safe and effective for patients with fatty liver disease and diabetes
- (2016) Jacqui Wise BMJ-British Medical Journal
- The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls
- (2015) Hassan Kahal et al. BMC Endocrine Disorders
- Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease
- (2014) Hui Fan et al. Arquivos Brasileiros de Endocrinologia e Metabologia
- Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes
- (2014) Ning Shao et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease
- (2013) H. Kahal et al. CLINICAL ENDOCRINOLOGY
- The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
- (2012) Takamasa Ohki et al. TheScientificWorldJOURNAL
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
- (2008) Gordon H Guyatt et al. BMJ-British Medical Journal
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now